{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:51:57Z","timestamp":1781833917513,"version":"3.54.5"},"reference-count":147,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["MSCA_0000032"],"award-info":[{"award-number":["MSCA_0000032"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PNRR-MR1-2022-12376725"],"award-info":[{"award-number":["PNRR-MR1-2022-12376725"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministry of Education and Merit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009886","name":"Puglia Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["PNRR-MR1-2022-12376725"],"award-info":[{"award-number":["PNRR-MR1-2022-12376725"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.isci.2026.115422","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:20:13Z","timestamp":1774038013000},"page":"115422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["CRISPR-Cas9 engineering of CAR-T cells: Can non-viral nanoparticles unlock safer and scalable genome editing?"],"prefix":"10.1016","volume":"29","author":[{"given":"Bruna","family":"My","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Galeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria Elena","family":"Palam\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Gigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.115422_bib1","unstructured":"Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products; Draft Guidance for Industry; Availability. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-development-chimeric-antigen-receptor-car-t-cell-products."},{"key":"10.1016\/j.isci.2026.115422_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01594","article-title":"Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions","volume":"10","author":"Greenbaum","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.115422_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115422_bib4","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.115422_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The Basic Principles of Chimeric Antigen Receptor Design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.115422_bib7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.115422_bib8","article-title":"CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115422_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.isci.2026.115422_bib14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115422_bib15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-025-03697-y","article-title":"Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies","volume":"25","author":"Nasiri","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2026.115422_bib17","article-title":"Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors","volume":"2","author":"Muliaditan","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2026.115422_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.isci.2026.115422_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.84","article-title":"the fourth-generation CAR T cells: Current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"10.1016\/j.isci.2026.115422_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2026.115422_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115422_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115422_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.115422_bib24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41422-023-00828-w","article-title":"CAR T cell design: approaching the elusive AND-gate","volume":"33","author":"Zhao","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.isci.2026.115422_bib25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.115422_bib26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cels.2020.08.002","article-title":"Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies","volume":"11","author":"Dannenfelser","year":"2020","journal-title":"Cell Syst."},{"key":"10.1016\/j.isci.2026.115422_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41571-025-01075-1","article-title":"Optimizing CAR T cell therapy for solid tumours: a clinical perspective","volume":"22","author":"Li","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115422_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41417-025-00931-7","article-title":"Barriers and solutions for CAR-T therapy in solid tumors","volume":"32","author":"Tu","year":"2025","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.isci.2026.115422_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.isci.2026.115422_bib30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2026.115422_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.115422_bib32","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.115422_bib33","doi-asserted-by":"crossref","first-page":"34341","DOI":"10.18632\/oncotarget.9114","article-title":"Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model","volume":"7","author":"Suarez","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.115422_bib34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib35","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.115422_bib36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.115422_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2026.115422_bib38","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","article-title":"Engineering the next generation of CAR-NK immunotherapies","volume":"114","author":"Biederst\u00e4dt","year":"2021","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.isci.2026.115422_bib39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib40","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, Activity, and Immune Correlates of Anti\u2013PD-1 Antibody in Cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib42","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.115422_bib43","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/psp4.12962","article-title":"Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome\/acute myeloid leukemia and solid tumors","volume":"12","author":"Xu","year":"2023","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.isci.2026.115422_bib44","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/bit.27882","article-title":"Strengthening the CAR-T cell therapeutic application using CRISPR\/Cas9 technology","volume":"118","author":"Nezhad","year":"2021","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.isci.2026.115422_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/bfgp\/elz042","article-title":"Applications and explorations of CRISPR\/Cas9 in CAR T-cell therapy","volume":"19","author":"Li","year":"2020","journal-title":"Brief. Funct. Genom."},{"key":"10.1016\/j.isci.2026.115422_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2026.115422_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.115422_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib51","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115422_bib52","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.115422_bib55","doi-asserted-by":"crossref","first-page":"10437","DOI":"10.1073\/pnas.1512503112","article-title":"Generation of knock-in primary human T cells using Cas9 ribonucleoproteins","volume":"112","author":"Schumann","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.115422_bib56","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115422_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115422_bib58","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/bloodadvances.2023010570","article-title":"CRISPR\/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model","volume":"8","author":"Neidemire-Colley","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.115422_bib59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib60","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103637","article-title":"PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours","volume":"39","author":"Wiede","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.isci.2026.115422_bib61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib62","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib63","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41587-022-01574-x","article-title":"Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases","volume":"41","author":"Tou","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib64","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1084\/jem.20171626","article-title":"Optimized RNP transfection for highly efficient CRI SPR\/Cas9-mediated gene knockout in primary T cells","volume":"215","author":"Seki","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.115422_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28244-5","article-title":"CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations","volume":"13","author":"H\u00f6ijer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115422_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115422_bib67","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2026.115422_bib68","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.115422_bib69","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/10430342251372474","article-title":"Risk and Benefit Assessment of Gene Therapy with Lentiviral Vectors and Hematopoietic Stem Cells: The Skysona Case","volume":"36","author":"Puig-Serra","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.isci.2026.115422_bib70","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.115422_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115422_bib72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115422_bib73","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/76458","article-title":"Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells","volume":"18","author":"Parveen","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib74","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and Design of Chimeric Antigen Receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.isci.2026.115422_bib75","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.omtm.2018.01.002","article-title":"Pharmacology of Recombinant Adeno-associated Virus Production","volume":"8","author":"Penaud-Budloo","year":"2018","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.isci.2026.115422_bib76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene Therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115422_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) \u2013 An overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.isci.2026.115422_bib78","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115422_bib79","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115422_bib80","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1101\/gr.231936.117","article-title":"CRISPR RNAs trigger innate immune responses in human cells","volume":"28","author":"Kim","year":"2018","journal-title":"Genome Res."},{"key":"10.1016\/j.isci.2026.115422_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2005840","article-title":"In vitro\u2013transcribed guide RNAs trigger an innate immune response via the RIG-I pathway","volume":"16","author":"Wienert","year":"2018","journal-title":"PLoS Biol."},{"key":"10.1016\/j.isci.2026.115422_bib82","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nbt.3290","article-title":"Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells","volume":"33","author":"Hendel","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413685","article-title":"Current Non-Viral-Based Strategies to Manufacture CAR-T Cells","volume":"25","author":"Gehrke","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.115422_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1032397","article-title":"Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies","volume":"13","author":"Singh","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115422_bib85","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115422_bib86","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","article-title":"Investigation of product-derived lymphoma following infusion of piggyBac -modified CD19 chimeric antigen receptor T cells","volume":"138","author":"Micklethwaite","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115422_bib87","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ymthe.2024.04.024","article-title":"Tc Buster transposon system to engineer primary immune cells","volume":"32","author":"Skeate","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115422_bib88","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.115422_bib89","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells","volume":"138","author":"Bishop","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115422_bib90","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ymthe.2024.04.024","article-title":"Evolution of the clinical-stage hyperactive TcBuster transposase as a platform for robust non-viral production of adoptive cellular therapies","volume":"32","author":"Skeate","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115422_bib91","doi-asserted-by":"crossref","DOI":"10.1186\/s40580-016-0064-z","article-title":"Rational engineering of physicochemical properties of nanomaterials for biomedical applications with nanotoxicological perspectives","volume":"3","author":"Navya","year":"2016","journal-title":"Nano Converg."},{"key":"10.1016\/j.isci.2026.115422_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.crimmu.2023.100073","article-title":"Nanoparticles cellular uptake, trafficking, activation, toxicity and in vitro evaluation","volume":"4","author":"Toscano","year":"2023","journal-title":"Curr. Res. Immunol."},{"key":"10.1016\/j.isci.2026.115422_bib93","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.3390\/cancers13174437","article-title":"Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible \u201cEPR Effect Enhancer\u201d to Improve Cancer Nanomedicine Efficacy","volume":"13","author":"Bonferoni","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.115422_bib94","doi-asserted-by":"crossref","first-page":"13202","DOI":"10.1039\/D3NR01332D","article-title":"Nanoparticles with transformable physicochemical properties for overcoming biological barriers","volume":"15","author":"Lu","year":"2023","journal-title":"Nanoscale"},{"key":"10.1016\/j.isci.2026.115422_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124799","article-title":"Effects of nanoparticle size, shape, and zeta potential on drug delivery","volume":"666","author":"\u00d6zt\u00fcrk","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.isci.2026.115422_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.128339","article-title":"Understanding protein-nanoparticle interactions leading to protein corona formation: In vitro - in vivo correlation study","volume":"256","author":"Marques","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.isci.2026.115422_bib97","doi-asserted-by":"crossref","first-page":"11773","DOI":"10.1021\/acsnano.7b08008","article-title":"A Decade of the Protein Corona","volume":"11","author":"Ke","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.isci.2026.115422_bib98","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.3390\/nano13243094","article-title":"Fixation and Visualization of Full Protein Corona on Lipid Surface of Composite Nanoconstruction","volume":"13","author":"Epanchintseva","year":"2023","journal-title":"Nanomaterials"},{"key":"10.1016\/j.isci.2026.115422_bib99","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.3390\/molecules29153482","article-title":"A Comprehensive Review of Nanoparticles: From Classification to Application and Toxicity","volume":"29","author":"Eker","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.isci.2026.115422_bib100","first-page":"757","article-title":"Protein Corona of Nanoparticles: Isolation and Analysis","volume":"1","author":"Sun","year":"2024","journal-title":"Chem. Bioeng."},{"key":"10.1016\/j.isci.2026.115422_bib101","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211530","article-title":"High-efficiency nonviral CRISPR\/Cas9-mediated gene editing of human T cells using plasmid donor DNA","volume":"219","author":"Oh","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.115422_bib102","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.4049\/jimmunol.1901396","article-title":"Efficient CRISPR\/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies","volume":"204","author":"N\u00fcssing","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.115422_bib103","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115422_bib104","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2026.115422_bib105","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.115422_bib106","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41592-019-0329-7","article-title":"One-step generation of modular CAR-T cells with AAV\u2013Cpf1","volume":"16","author":"Dai","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.isci.2026.115422_bib107","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib108","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib109","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","article-title":"Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function","volume":"175","author":"Shifrut","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.115422_bib110","doi-asserted-by":"crossref","first-page":"E4051","DOI":"10.1073\/pnas.1801340115","article-title":"Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation","volume":"115","author":"Shang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.115422_bib111","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp9371","article-title":"TET2 regulates early and late transitions in exhausted CD8 + T cell differentiation and limits CAR T cell function","volume":"10","author":"Dimitri","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.isci.2026.115422_bib112","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115422_bib113","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1158\/0008-5472.CAN-18-0030","article-title":"CRISPR\/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells","volume":"78","author":"Jung","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.115422_bib114","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib115","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib116","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acsnano.7b07874","article-title":"Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles","volume":"12","author":"Luo","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.isci.2026.115422_bib117","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.apsb.2024.08.030","article-title":"Optimized lipid nanoparticles enable effective CRISPR\/Cas9-mediated gene editing in dendritic cells for enhanced immunotherapy","volume":"15","author":"Mao","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.isci.2026.115422_bib118","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.115422_bib119","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.115422_bib120","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1182\/blood-2022-166432","article-title":"CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study","volume":"140","author":"McGuirk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115422_bib121","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1200\/JCO.2024.42.16_suppl.7025","article-title":"A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): Updated phase 1 results from the ANTLER trial","volume":"42","author":"Hu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115422_bib122","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1200\/JCO.2021.39.15_suppl.2529","article-title":"First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed\/refractory large B-cell lymphoma (R\/R LBCL): ALPHA2 study","volume":"39","author":"Locke","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115422_bib123","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/156652311796150354","article-title":"Immune responses to AAV in clinical trials","volume":"11","author":"Mingozzi","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.isci.2026.115422_bib124","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115422_bib125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.isci.2026.115422_bib126","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115422_bib127","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.115422_bib128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.isci.2026.115422_bib129","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.115422_bib130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib131","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.115422_bib132","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.isci.2026.115422_bib133","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Mohamed","year":"2019","journal-title":"Sci. Technol. Adv. Mater."},{"key":"10.1016\/j.isci.2026.115422_bib134","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"10.1016\/j.isci.2026.115422_bib135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.115422_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.isci.2026.115422_bib137","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.115422_bib138","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-023-01783-1","article-title":"Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies","volume":"22","author":"Huang","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.115422_bib139","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","article-title":"Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","volume":"29","author":"Anderson","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115422_bib140","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.isci.2026.115422_bib141","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.115422_bib142","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib143","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/nnano.2012.207","article-title":"Biomolecular coronas provide the biological identity of nanosized materials","volume":"7","author":"Monopoli","year":"2012","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.isci.2026.115422_bib144","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1073\/pnas.0608582104","article-title":"Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles","volume":"104","author":"Cedervall","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.115422_bib145","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.isci.2026.115422_bib146","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/am.2017.185","article-title":"Lipid nanoparticle-mediated efficient delivery of CRISPR\/Cas9 for tumor therapy","volume":"9","author":"Zhang","year":"2017","journal-title":"NPG Asia Mater."},{"key":"10.1016\/j.isci.2026.115422_bib147","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1021\/acsami.9b23084","article-title":"Reshaping Tumor Immune Microenvironment through Acidity-Responsive Nanoparticles Featured with CRISPR\/Cas9-Mediated Programmed Death-Ligand 1 Attenuation and Chemotherapeutics-Induced Immunogenic Cell Death","volume":"12","author":"Tu","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226007972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226007972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:20:57Z","timestamp":1781832057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226007972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":147,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2589004226007972"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.115422","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRISPR-Cas9 engineering of CAR-T cells: Can non-viral nanoparticles unlock safer and scalable genome editing?","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.115422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115422"}}